Correction to: InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design

Diabetes Ther. 2020 Aug;11(8):1907-1908. doi: 10.1007/s13300-020-00853-7.

Tadej Battelino¹, Zsolt Bosnyak², Thomas Danne³, Bhaswati Mukherjee², Steve Edelman⁴, Valerie Pilorget², Pratik Choudhary^{5

6}, Eric Renard^{7

8

9}, Richard Bergenstal¹⁰

¹ UMC-University Children's Hospital, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. tadej.battelino@mf.uni-lj.si.
² Sanofi S.A., Paris, France.
³ Diabetes Centre for Children and Adolescents, Children's and Youth Hospital "Auf Der Bult", Hannover, Germany.
⁴ University of California, San Diego, CA, USA.
⁵ King's College Hospital NHS Foundation Trust, London, UK.
⁶ Department of Diabetes, School of Life Course Sciences, King's College London, London, UK.
⁷ Department of Endocrinology, Diabetes and Nutrition, Montpellier University Hospital, University of Montpellier, Montpellier, France.
⁸ Institute of Functional Genomics, University of Montpellier, Montpellier, France.
⁹ INSERM Clinical Investigation Centre, Montpellier, France.
¹⁰ International Diabetes Center at Park Nicollet, Minneapolis, USA.

Abstract

In the original publication, the timing of baseline CGM assessment was incorrectly stated.